Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of RA \>/= 3 months duration.~* Continuous treatment of MTX 10 - 25 mg/week (or per local labeling requirements if the dose range differs) for at least 12 weeks before screening visit and on a stable dose for 8 weeks before screening visit.~* Active disease defined as: at least 6/66 swollen and 8/68 tender joints and high sensitivity C-reactive protein \> 10 mg/L.~Exclusion criteria:~* Age \< 18 years.~* Use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks of the screening visit.~* Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks of the screening visit.~* Prior treatment with a tumor necrosis factor (TNF)-alpha inhibitor, or other biological disease modifying anti-rheumatoid drug (DMARD) or Janus Kinase inhibitor.~* New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors within 4 weeks of the screening visit.~* Treatment with traditional oral DMARD /immunosuppressive agents other than MTX within 4 weeks or 12 weeks before the screening visit, depending on DMARD.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab Open Label run-in (Type: EXPERIMENTAL): Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
- Etanercept + MTX (Randomized) (Type: ACTIVE_COMPARATOR): Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
- Sarilumab 150 mg + MTX (Randomized) (Type: EXPERIMENTAL): Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
- Sarilumab 200 mg + MTX (Randomized) (Type: EXPERIMENTAL): Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
- Sarilumab 150 mg + MTX Open Label Sub-study (Type: EXPERIMENTAL): Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.

Based on this trial design, predict the completion outcome and termination type (if applicable).